Sreedhar Subramanian

25PUBLICATIONS
41CO-AUTHORS
Innate immunityEnvironmental epidemiologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Immunology not elsewhere classifiedFood properties (incl. characteristics and health benefits)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Jan 22, 2025
Delays in Initiating Biologic Therapy in Patients with Inflammatory Bowel Disease-Perception and Reality.

Anish J Kuriakose Kuzhiyanjal, Sreedhar Subramanian, Jimmy K Limdi

|Aug 03, 2024
Comparative Safety and Effectiveness of Ustekinumab and Anti-TNF in Elderly Crohn's Disease Patients.

Gerum Gashaw Gebeyehu, Giacomo Broglio, Eleanor Liu

|Nov 27, 2022
Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn's Disease Patients.

Gerum Gashaw Gebeyehu, Joseph Fiske, Eleanor Liu

|Oct 05, 2022
Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study.

Aamir Saifuddin, Alexandra J Kent, Shameer J Mehta

|Jun 24, 2022
Editorial: intravenous to subcutaneous vedolizumab-switch without glitch!

Vinoth Nadesalingam, Sreedhar Subramanian

|Apr 07, 2022
Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.

Philip J Smith, Lisa Critchley, Daniel Storey

Pageof 5

Frequent Collaborators

5 joint publications

Shaji Sebastian

4 joint publications

Nicholas A Kennedy

4 joint publications

Kamal V Patel

3 joint publications

Shameer Mehta